Experienced in Chronic Myelogenous Leukemia (CML)

Dr. Elyse C. Schneiderman

Hematology Oncology
1 Salt Creek Ln, 
Hinsdale, IL 
Experienced in Chronic Myelogenous Leukemia (CML)
1 Salt Creek Ln, 
Hinsdale, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elyse Schneiderman is a Hematologist Oncology provider in Hinsdale, Illinois. Dr. Schneiderman is rated as an Experienced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Anal Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Her clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1 Salt Creek Ln, Hinsdale, IL 60521

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Richard A. Larson
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Richard A. Larson
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (16.5 miles away)
773-702-1000
Languages Spoken:
English, Arabic, Egyptian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Larson is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Larson is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Inflammatory Breast Cancer, Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Larson is currently accepting new patients.

Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Tulio E. Rodriguez
Hematology Oncology | Hematology
Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Tulio E. Rodriguez
Hematology Oncology | Hematology

City Of Hope Medical Group Of Illinois PLLC

2520 Elisha Ave, 
Zion, IL 
 (43.8 miles away)
847-872-4561
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Tulio Rodriguez is a Hematologist Oncology specialist and a Hematologist in Zion, Illinois. Dr. Rodriguez is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rodriguez is currently accepting new patients.

Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Saadia Yunus
Hematology Oncology | Hematology | Oncology
Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Saadia Yunus
Hematology Oncology | Hematology | Oncology

Dupage Medical Group Ltd

430 Warrenville Rd, Suite 210, 
Lisle, IL 
 (7.1 miles away)
630-432-6180
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Saadia Yunus is a Hematologist Oncology specialist and a Hematologist in Lisle, Illinois. Dr. Yunus is rated as an Advanced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Anemia, Familial Colorectal Cancer, Colorectal Cancer, and Philadelphia-Negative Chronic Myeloid Leukemia. Dr. Yunus is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schneiderman's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile